Last updated: 07/02/2019 09:41:05
Investigating the Efficacy of an Occluding Dentifrice in Providing Relief from Dentinal Hypersensitivity
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief from Dentinal Hypersensitivity
Trial description: This single center, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Change From Baseline in Schiff Sensitivity Score on Day 3
Timeframe: Baseline, Day 3
Secondary outcomes:
Change From Baseline in Schiff Sensitivity Score after single use
Timeframe: Baseline, after single use (after 5 minutes)
Change From Baseline in Tactile Threshold Immediately after Single Use and on Day 3
Timeframe: Baseline, after single use (after 5 minutes) and on Day 3
Interventions:
Drug: stannous fluoride
Drug: sodium monofluorophosphate
Enrollment:
242
Observational study model:
Not applicable
Primary completion date:
2016-12-05
Time perspective:
Not applicable
Clinical publications:
Creeth J, Gallob J, Sufi F, Qaqish J, Gomez-Pereira P, Budhawant C, Goyal C. Randomised clinical studies investigating immediate and short-term efficacy of an occluding toothpaste in providing dentine hypersensitivity relief. BMC Oral Health. 2019 Jun 4;19(1):98. doi: 10.1186/s12903-019-0781-x. PMID:31164116
Medical condition
Dentin Sensitivity
Product
SKF46655, SKF46656, sodium fluoride
Collaborators
Not applicable
Study date(s)
March 2016 to May 2016
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Aged 18-65 years inclusive
- Women who are known to be pregnant. Females of child bearing potential who have a positive urine pregnancy test or who are breast feeding
- Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
Inclusion and exclusion criteria
Inclusion criteria:
- Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. -Aged 18-65 years inclusive -Understands and is willing, able and likely to comply with all study procedures and restrictions -Good general and mental health with, in the opinion of the investigator or medically qualified designee: No clinically significant, relevant abnormalities of medical history or oral examination and Absence of any condition that would impact on the participant’s safety or wellbeing or affect the individual’s ability to understand and follow study procedures and requirements -Self-reported history of DH lasting more than six months but not more than 10 years at screening -Minimum of 20 natural teeth at screening -Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants that meet all of the following criteria: Signs of facial/cervical gingival recession and/or signs of erosion or abrasion (EAR) Tooth with MGI score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of less than or equal to (≤)1 and Tooth with signs of sensitivity measured by qualifying evaporative air assessment (Y[Yes]/N[No] response) screening -Minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars),that meet all of the following criteria at Baseline: Tooth with signs of sensitivity, measured by qualifying tactile stimulus (Yeaple ≤ 20g) and evaporative air assessment (Schiff sensitivity score ≥ 2)
Exclusion criteria:
- Women who are known to be pregnant. Females of child bearing potential who have a positive urine pregnancy test or who are breast feeding -Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients -Previous participation in this study or participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit -Recent history (within the last year) of alcohol or other substance abuse -An employee of the sponsor or the study site or members of their immediate family -Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes or Any condition which, in the opinion of the investigator, causes xerostomia -Dental prophylaxis within 4 weeks of Screening, tongue or lip piercing or presence of dental implants, gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening and teeth bleaching within 8 weeks of Screening -Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening -Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine -Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice in the opinion of the Investigator -Use of an oral care product indicated for the relief of dentine hypersensitivity within 8 weeks of screening -Daily doses of medication/treatments which, in the opinion of the investigator, could interfere with the perception of pain. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, anti-depressants, mood-altering and anti-inflammatory drugs. -Currently taking antibiotics or has taken antibiotics within 2 weeks of Baseline, Daily dose of a medication which, in the opinion of the investigator, is causing xerostomia
Trial location(s)
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89146
Status
Study Complete
Study documents
Statistical analysis plan
Available language(s): English
Protocol
Available language(s): English
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2016-12-05
Actual study completion date
2016-12-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Randomised clinical studies investigating immediate and short-term efficacy of an occluding toothpaste in providing dentine hypersensitivity relief
Click hereAccess to clinical trial data by researchers
Visit website